Claim · 2026-02-26 · publication · Stated in source · Supported

Generate Biomedicines' IPO prospectus (26 February 2026) describes the Generate Platform as integrating generative and predictive models, including "diffusion-based models (such as our Chroma model)", with experimental systems.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Generate Biomedicines, Inc. IPO prospectus (424B4) → states provision → platform description: generative and predictive models, including diffusion-based models such as Chroma

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Generate Biomedicines, Inc. IPO prospectus (424B4)states provision ↓platform description: generative and predictive models, including diffusion-based models such as Chroma

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Provision: Statement · provision ID co-generate-chroma-2026
Date: 2026-02-26 · publication Records dated 2026 →

Scope and limitsThe company's description of its platform; the record gives no model detail and is not evidence of what the models achieve. The Chroma research paper is not recorded here. The surrounding passage describes laboratory systems at a high level; only the platform-level sentence is quoted.

The evidence 01

primary sourceSupports the claim

Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock

Generate Biomedicines, Inc. (filed with the US SEC) · 2026-02-26

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“The Generate Platform integrates generative and predictive models that learn design principles from proprietary data—e.g., diffusion-based models (such as our Chroma model) and graph neural networks, among other architectures”

Location in source Prospectus summary, "The Generate Platform"

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Generate Biomedicines, Inc. (filed with the US SEC)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Generate Biomedicines, Inc. (filed with the US SEC), “Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock”, 2026-02-26.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (29 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item B10) re-read the record’s sources and found full support. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.

Date. Prospectus date.

Record ID aib-co-generate-chroma-2026